Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6254714 | 1.00 | KDM1A (0.47) | KDM1AMAOAMAOBBACE1TDP1 | |
| Hydrochloric Acid SCHEMBL7564142 | 0.98 | KDM1A (0.49) | KDM1AMAOAMAOBBACE1TDP1 | |
| Oxalic Acid SCHEMBL7569162 | 0.91 | KDM1A (0.41) | KDM1AMAOAMAOBALDH1A1MAPT | |
| SCHEMBL7109309 | 0.85 | KDM1A (0.38) | KDM1AMAOAMAOBBACE1MAPK1 | |
| SCHEMBL7110629 | 0.83 | ALDH1A1 (0.40) | KDM1AMAOAMAOBBACE1MAPK1 | |
| SCHEMBL10271980 | 0.81 | KDM1A (0.44) | KDM1AMAOAMAOBALDH1A1MAPT | |
| SCHEMBL10340138 | 0.80 | KMT2A (0.37) | BACE1MAPK1ALDH1A1MAPTNPC1 | |
| SCHEMBL5439563 | 0.77 | BACE1 (0.45) | KDM1ABACE1HTR2C | |
| SCHEMBL6257456 | 0.77 | TAAR1 (0.47) | KDM1AMAOAMAOBMAPK1ALDH1A1 | |
| SCHEMBL12652517 | 0.77 | NOS1 (0.40) | MAPK1ALDH1A1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299103-B1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | claimed |
| US-6420566-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | claimed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | claimed |
| EP-1299103-B1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | disclosed |
| EP-1299103-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-6420566-B2 | NITRIC OXIDE SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2001093867-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | ALK, QDPR, CYP3A7 | KDM1A 1799/4885MAOA 667/4885MAOB 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.